Iterion Therapeutics, Inc. logo

Iterion Therapeutics, Inc.

Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://iteriontherapeutics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2450 West Holcombe Boulevard, TX, 77021
Houston
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/iterion-therapeutics” connections=”true” suffix=””]